FDA Announces NASEM Study of U.S. Infant Formula Supply, Regulation, Market
The U.S. Food and Drug Administration (FDA) has announced that the National Academies of Sciences, Engineering, and Medicine (NASEM) will conduct an independent study on challenges in the U.S. infant formula supply, market competition, and regulation.
The study will explore the current state of the U.S. infant formula market, including the diversity of manufacturers; the types of formulas produced (e.g., non-specialty or specialty, powdered or liquid); manufacturing facilities and their production and production capacities; the amounts of infant formula produced domestically versus the amounts imported; and other factors. The study will also examine how these factors compare to those of the market prior to the COVID-19 pandemic, and just prior to the Abbott Nutrition recall that occurred in February 2022 and precipitated a months-long supply and safety crisis.